Home > OJBIPHY>
Biography

Prof. Abass Alavi
University of Pennsylvania, USA

Email: abass.alavi@uphs.upenn.edu


Qualifications

1987 Professor of Psychiatry, University of Pennsylvania, USA

1982 Professor of Neurology, University of Pennsylvania, USA

1977 Associate Professor of Radiology, University of Pennsylvania, USA


Publications (Selected)

  1. Abass Alavi. (2011) “Molecular Imaging with PET”, “The Critical Role of PET/CT in the Management of Patients with Cancer”, “The Evolving Role of PET Imaging in Assessing Infection and Inflammation”, “Current and Future Applications of PET in Neuro-Psychiatric Disorders”, PET/CT Cairo Symposium, Cairo, Egypt.
  2. Abass Alavi. (2010) Inaugural Speaker, CV Imaging Working Group of the Penn Cardiovascular Institute, Penn CVI Cardiology/Radiology seminar series, Philadelphia, PA.
  3. Abass Alavi. (2010) “Emerging Role of Molecular Imaging with PET in the Day to Day practice of Medicine”, Grand Rounds, Radiologic Society of New Jersey, Robert Wood Johnson University Hospital, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ.
  4. Abass Alavi. (2010) “Emerging Role of PET and PET-CT in Assessing Musculoskeletal Disorders” Biomedical Engineering Graduate Students Seminar”, Department of Orthopaedic Surgery & Rehabilitation Medicine, SUNY Downstate Medical Center, Brooklyn, New York.
  5. Abass Alavi. (2010) Panel Member, Scientific Review Panel, R 21 applications, Clinical Studies of Bisphosphonate Therapy and Osteonecrosis of the Jaw (R21). National Institute of Dental and Craniofacial Research, Teleconference.
  6. Abass Alavi. (2010) “Emerging Role of Hybrid Imaging for Optimal Assessment of Molecular Alterations in Neuropsychiatric Disorders and Its Implications for Individualized Treatments in the Future”, American Society of Functional Neuroradiology, Vic Haughton Honorary Lecture, Wynn Encore, Las Vegas.
  7. Abass Alavi. (2010) “Molecular Imaging with PET, A Revolution in Medicine”, ”Clinical Applications of PET in Lymphoma and Pediatrics”, ”Emerging Role of PET in Assessing and monitoring Patients with Suspected and Proven infection and inflammation”, ”Critical Role of PET in the Management of patients with Central Nervous System Disorders” Nuclear Medicine Section, Department of Medical Imaging, King Fahad Hospital, Riyadh, Kingdom of Saudi Arabia.
  8. Abass Alavi. (2010) “Emerging Role of PET and PET-CT in the Day to Day Practice of Medicine”, Grand Rounds, Depart. of Internal Medicine, Cleveland Clinic, Cleveland, OH.
  9. Abass Alavi. (2010) “Novel Quantitative Techniques for Defining Tumor Biology; a New Paradigm in Cancer Research”, Department of Nuclear Medicine Research Conference, Cleveland Clinic Taussig Cancer Center, Cleveland, OH.
  10. Abass Alavi. (2010) “FDG-PET: A brief history to current perspectives in oncologic imaging”, Grand Rounds, Department of Nuclear Medicine, Cleveland Clinic Taussig Cancer Center, Cleveland, OH.
  11. Abass Alavi. (2010) Scientific Review Panel, Nutrition Obesity Research Centers (P30) applications, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Washington, DC.
  12. Abass Alavi. (2010) Member, Scientific Review Panel, Nanotechnology R25T and K99/R00 Applications for National Cancer Institute, National Institutes of Health, Rockville, MD.
  13. Abass Alavi. (2010) “Revolutionary Impact of Molecular Imaging  with PET on Research and the Day to Day Practice of Medicine”, Dermatology Research Seminar Series, Department of Dermatology School of Medicine, University of Pennsylvania, Phila., PA.
  14. Abass Alavi. (2010) “18F-Fluorodeoxyglucose-Positron Emission Tomography for the detection of infections and aseptic inflammatory disorders”, CASE Seminars of the Food and Drug Administration, Division of Antimicrobial and Ophthalmology Products, Center for Drug Evaluation and Research, FDA White Oak campus, Silver Springs, MD.
  15. Abass Alavi. (2010) Medical Education Program, Genzyme, Inc., Cambridge, MA.
  16. Abass Alavi. (2010) Application of Biomarkers and Imaging to Early Phase Studies with an Anti-LOXL2 Antibody, Arresto BioSciences, Palo Alto, CA.